The Food and Drug Administration on Friday paved the way for children ages 5 to 11 to get Pfizer’s COVID-19 vaccine. The FDA cleared kid-size doses — just a third of the amount given to teens and adults — for emergency use, and up to 28 million more American children could be eligible for vaccinations as early as next week.
Health officials are closing in on a decision about Pfizer’s COVID-19 vaccine for kids ages 5-11, but a new survey shows significant hesitancy among parents to get young children vaccinated.
The FDA is considering whether to authorize the Pfizer COVID-19 vaccine for children ages 5-11, after its advisory panel voted to recommend it for emergency use authorization. If the FDA signs off next week, we could see shots in arms for those kids as soon as November.
Elementary school kids are one step closer to getting a vaccine. The FDA is now considering whether to authorize the Pfizer vaccine for children ages 5-11, after its advisory panel voted to recommend it Tuesday. If the FDA does authorize it, a CDC panel that meets next week would also have to give the thumbs up, and the director would have the final say.
U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.
Only 15% of seniors have received a COVID-19 vaccine booster, according to the FDA.
An announcement about mixing and matching coronavirus boosters is expected to come from the FDA. This comes as more people get vaccinated, while COVID-19 infections, deaths and hospitalizations appear to steadily fall across the country. Meanwhile, the battle against vaccine mandates continues.
More booster shots could be on the way. An FDA advisory committee voted on Moderna’s booster dose Thursday.
U.S. health advisers said Thursday that some Americans who received Moderna’s COVID-19 vaccine should get a half-dose booster to bolster protection against the virus.
Vaccine advisors are set to discuss mixing and matching COVID-19 vaccines Friday.
